Evotec to discover and develop first-in-class oncology therapeutics in research tie-up

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Evotec, Oncology, Drug discovery, Drug development

Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.

The research collaboration will leverage Evotec’s new proprietary drug discovery platform TargetAlloMod and is initially set to last two years.

The platform has applicability across therapeutic areas, including a suite of assay principles and computational tools “to assess and screen extracellular receptor targets for shedding and the induction of shedding by small molecule allosteric modulators,”​ according to the company.

Under terms of the agreement, the Mark Foundation for Cancer Research will provide research funding to Evotec, which will be in charge of partnerships.

The NY-based foundation will expand it is grant portfolio – focused on oncology research and drug discovery – with any potential financial returns.

Financial terms were not disclosed.

Evotec earlier this month announced ​a partnership with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.

The strategic public-private partnership with the Global Antibiotic Research and Development Partnership (GARDP) will address the threat posed by antimicrobial resistance (AMR).

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more